| Year |
Citation |
Score |
| 2020 |
Galbraith K, Kumar A, Abdullah KG, Walker JM, Adams SH, Prior T, Dimentberg R, Henderson FC, Mirchia K, Sathe AA, Viapiano MS, Chin LS, Corona RJ, Hatanpaa KJ, Snuderl M, ... ... Brem S, et al. Molecular Correlates of Long Survival in IDH-Wildtype Glioblastoma Cohorts. Journal of Neuropathology and Experimental Neurology. PMID 32647886 DOI: 10.1093/Jnen/Nlaa059 |
0.371 |
|
| 2020 |
Henderson F, Brem S, O'Rourke DM, Nasrallah M, Buch VP, Young AJ, Doot RK, Pantel A, Desai A, Bagley SJ, Nabavizadeh SA. F-Fluciclovine PET to distinguish treatment-related effects from disease progression in recurrent glioblastoma: PET fusion with MRI guides neurosurgical sampling. Neuro-Oncology Practice. 7: 152-157. PMID 32206320 DOI: 10.1093/Nop/Npz068 |
0.31 |
|
| 2020 |
Akbari H, Rathore S, Bakas S, Nasrallah MP, Shukla G, Mamourian E, Rozycki M, Bagley SJ, Rudie JD, Flanders AE, Dicker AP, Desai AS, O'Rourke DM, Brem S, Lustig R, et al. Histopathology-validated machine learning radiographic biomarker for noninvasive discrimination between true progression and pseudo-progression in glioblastoma. Cancer. PMID 32129893 DOI: 10.1002/Cncr.32790 |
0.31 |
|
| 2020 |
Huang M, Zhang D, Wu JY, Xing K, Yeo E, Li C, Zhang L, Holland E, Yao L, Qin L, Binder ZA, O'Rourke DM, Brem S, Koumenis C, Gong Y, et al. Wnt-mediated endothelial transformation into mesenchymal stem cell-like cells induces chemoresistance in glioblastoma. Science Translational Medicine. 12. PMID 32102932 DOI: 10.1126/Scitranslmed.Aay7522 |
0.33 |
|
| 2020 |
Henderson F, Brem S, Hussain J, Buch L, Maloney E, Singhal S, Lee JYK. Second window indocyanine green localizes CNS lymphoma in real time in the operating room: report of two cases. British Journal of Neurosurgery. 1-5. PMID 32009484 DOI: 10.1080/02688697.2020.1716945 |
0.313 |
|
| 2020 |
Henderson F, Abdullah KG, Verma R, Brem S. Tractography and the connectome in neurosurgical treatment of gliomas: the premise, the progress, and the potential. Neurosurgical Focus. 48: E6. PMID 32006950 DOI: 10.3171/2019.11.Focus19785 |
0.308 |
|
| 2020 |
Reardon DA, Brem S, Desai AS, Bagley SJ, Kurz SC, De La Fuente MI, Nagpal S, Welch MR, Hormigo A, Carroll N, Bartra SK, Campbell P, Bhatt K, Lowy I, Boyer J, et al. INO-5401 and INO-9012 delivered intramuscularly (IM) with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma (GBM): Interim results. Journal of Clinical Oncology. 38: 2514-2514. DOI: 10.1200/Jco.2020.38.15_Suppl.2514 |
0.367 |
|
| 2020 |
Sampson JH, Achrol A, Aghi MK, Bankiewicz K, Bexon M, Brem S, Brenner AJ, Chandhasin C, Chowdhary SA, Coello M, Das S, Han SJ, Kesari S, Merchant F, Merchant N, et al. MDNA55 survival in recurrent glioblastoma (rGBM) patients expressing the interleukin-4 receptor (IL4R) as compared to a matched synthetic control. Journal of Clinical Oncology. 38: 2513-2513. DOI: 10.1200/Jco.2020.38.15_Suppl.2513 |
0.371 |
|
| 2020 |
Bagley SJ, Nabavizadeh SA, Till J, Abdalla A, Sanga H, Mays J, Prior T, Jurgielewicz A, Guiry S, Davtyan K, Yee SS, Binder ZA, O'Rourke DM, Brem S, Desai AS, et al. A prospective validation cohort study of baseline plasma cell-free DNA (cfDNA) as a prognostic biomarker in newly diagnosed glioblastoma (GBM). Journal of Clinical Oncology. 38: 2508-2508. DOI: 10.1200/Jco.2020.38.15_Suppl.2508 |
0.309 |
|
| 2020 |
Skolnik J, Reardon D, Brem S, Desai A, Bagley S, Kurz S, Fuente Mdl, Nagpal S, Welch M, Sacchetta B, Bartra S, Bredlau A, Lowy I, Kraynyak K, Morrow M, et al. P858 An open-label, multi-center trial of INO-5401 and INO-9012 delivered by electroporation (EP) in combination with cemiplimab in subjects with newly-diagnosed glioblastoma (GBM) Journal For Immunotherapy of Cancer. 8: A8.1-A8. DOI: 10.1136/Lba2019.12 |
0.382 |
|
| 2019 |
Jacob F, Salinas RD, Zhang DY, Nguyen PTT, Schnoll JG, Wong SZH, Thokala R, Sheikh S, Saxena D, Prokop S, Liu DA, Qian X, Petrov D, Lucas T, Chen HI, ... ... Brem S, et al. A Patient-Derived Glioblastoma Organoid Model and Biobank Recapitulates Inter- and Intra-tumoral Heterogeneity. Cell. PMID 31883794 DOI: 10.1016/J.Cell.2019.11.036 |
0.386 |
|
| 2019 |
Makhlin I, Salinas RD, Zhang D, Jacob F, Ming GL, Song H, Saxena D, Dorsey JF, Nasrallah MP, Morrissette JJ, Binder ZA, O'Rourke DM, Desai AS, Brem S, Bagley SJ. Clinical activity of the tyrosine kinase inhibitor osimertinib in -mutant glioblastoma. Cns Oncology. 8: CNS43. PMID 31769726 DOI: 10.2217/Cns-2019-0014 |
0.311 |
|
| 2019 |
Sheikh S, Saxena D, Tian X, Amirshaghaghi A, Tsourkas A, Brem S, Dorsey JF. An integrated stress response agent that modulates DR5 dependent TRAIL synergy reduces patient derived glioma stem cell viability. Molecular Cancer Research : McR. PMID 30642878 DOI: 10.1158/1541-7786.Mcr-18-0276 |
0.339 |
|
| 2019 |
Fried JG, Lariviere MJ, Parikh RB, Sullivan PZ, Kanter GP, Lee JY, Malhotra NR, Brem S, Ozturk AK, Schuster JM, Grady MS, Evans TL, Alonso-Basanta M, Jones JA, Kurtz R, et al. Design and implementation of outpatient-based rapid MRI protocols to rule out metastatic spinal cord compression and brain metastases. Journal of Clinical Oncology. 37: e18307-e18307. DOI: 10.1200/Jco.2019.37.15_Suppl.E18307 |
0.31 |
|
| 2019 |
Reardon D, Nagpal S, Soltys S, Brem S, Omuro A, Fuente MDL, Bredlau A, Lowy I, Fury M, Morrow M, Kraynyak K, McMullan T, Santo AL, Sacchetta B, Skolnik J. Abstract CT114: INO-5401 and INO-9012 delivered by electroporation (EP) in combination with cemiplimab (REGN2810) in newly-diagnosed glioblastoma (GBM) (NCT03491683) Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Ct114 |
0.387 |
|
| 2019 |
Salinas R, Zhang D, Jacob F, Nguyen P, Sheikh S, Prokop S, Dorsey JF, Nasrallah M, Brem S, O’Rourke DM, Ming G, Song H. A Patient-Derived Glioblastoma Organoid Model Maintains Intertumoral and Intratumoral Heterogeneity for Therapeutic Testing Neurosurgery. 66. DOI: 10.1093/Neuros/Nyz310_640 |
0.384 |
|
| 2019 |
Cho SS, Ramayya AG, Teng CW, Brem S, Singhal S, Lee JYK. Intraoperative Near-Infrared Fluorescence Imaging With Second-Window Indocyanine-Green Offers Accurate and Real-Time Correction for Brain Shift and Anatomic Inconsistencies in Framless Neuronavigation Neurosurgery. 66. DOI: 10.1093/Neuros/Nyz310_460 |
0.407 |
|
| 2019 |
Cloughesy T, Petrecca K, Walbert T, Butowski N, Salacz M, Perry J, Damek D, Bota D, Bettegowda C, Zhu J, Iwamoto F, Placantonakis D, Martinez N, Elder JB, Kaptain G, ... ... Brem S, et al. LTBK-08. TOCA 511 & TOCA FC VERSUS STANDARD OF CARE IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA Neuro-Oncology. 21: vi284-vi284. DOI: 10.1093/Neuonc/Noz219.1199 |
0.349 |
|
| 2019 |
Bagley S, Nabavizadeh S, Mays J, Till J, Yee S, Ware J, Guiry S, Nasrallah M, Levy S, Sarchiapone W, Hussain J, Prior T, Cucciara A, Binder Z, O’Rourke D, ... Brem S, et al. PATH-49. CLINICAL UTILITY OF PLASMA CELL-FREE DNA IN ADULT PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA – A PILOT PROSPECTIVE STUDY Neuro-Oncology. 21: vi154-vi154. DOI: 10.1093/Neuonc/Noz175.645 |
0.349 |
|
| 2019 |
Salinas R, Zhang D, Jacob F, Nguyen P, Sheikh S, Prokop S, Dorsey J, Nasrallah M, Brem S, O’Rourke D, Ming G, Song H. TMOD-25. GLIOBLASTOMA ORGANOIDS: A MODEL SYSTEM FOR PATIENT-SPECIFIC THERAPEUTIC TESTING Neuro-Oncology. 21: vi268-vi268. DOI: 10.1093/Neuonc/Noz175.1124 |
0.39 |
|
| 2018 |
Wang S, O'Rourke DM, Chawla S, Verma G, Nasrallah MP, Morrissette JJD, Plesa G, June CH, Brem S, Maloney E, Desai A, Wolf RL, Poptani H, Mohan S. Multiparametric magnetic resonance imaging in the assessment of anti-EGFRvIII chimeric antigen receptor T cell therapy in patients with recurrent glioblastoma. British Journal of Cancer. PMID 30478409 DOI: 10.1038/S41416-018-0342-0 |
0.321 |
|
| 2018 |
Liu T, Ma W, Xu H, Huang M, Zhang D, He Z, Zhang L, Brem S, O'Rourke DM, Gong Y, Mou Y, Zhang Z, Fan Y. PDGF-mediated mesenchymal transformation renders endothelial resistance to anti-VEGF treatment in glioblastoma. Nature Communications. 9: 3439. PMID 30150753 DOI: 10.1038/S41467-018-05982-Z |
0.338 |
|
| 2018 |
Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, Heth JA, Salacz M, Taylor S, D'Andre SD, Iwamoto FM, Dropcho EJ, Moshel YA, Walter KA, Pillainayagam CP, ... ... Brem S, et al. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. Journal of Translational Medicine. 16: 142. PMID 29843811 DOI: 10.1186/S12967-018-1507-6 |
0.317 |
|
| 2018 |
Wang Q, He Z, Huang M, Liu T, Wang Y, Xu H, Duan H, Ma P, Zhang L, Zamvil SS, Hidalgo J, Zhang Z, O'Rourke DM, Dahmane N, Brem S, et al. Vascular niche IL-6 induces alternative macrophage activation in glioblastoma through HIF-2α. Nature Communications. 9: 559. PMID 29422647 DOI: 10.1038/S41467-018-03050-0 |
0.301 |
|
| 2018 |
Parker D, Alappatt J, Elliott M, Brem S, Verma R. COMP-03. TUMOR CONNECTOME: INSIGHT INTO THE IMPACT OF CNS NEOPLASIA AND THERAPY ON THE BRAIN NETWORK Neuro-Oncology. 20: vi64-vi64. DOI: 10.1093/Neuonc/Noy148.258 |
0.35 |
|
| 2017 |
Stupp R, Taillibert S, Kanner A, Read W, Steinberg DM, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Di Meco F, Lieberman F, Zhu JJ, Stragliotto G, Tran DD, ... Brem S, et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. Jama. 318: 2306-2316. PMID 29260225 DOI: 10.1001/Jama.2017.18718 |
0.364 |
|
| 2017 |
O'Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, Martinez-Lage M, Brem S, Maloney E, Shen A, Isaacs R, Mohan S, Plesa G, Lacey SF, Navenot JM, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Science Translational Medicine. 9. PMID 28724573 DOI: 10.1126/Scitranslmed.Aaa0984 |
0.405 |
|
| 2017 |
Stupp R, Taillibert S, Kanner A, Read W, Steinberg DM, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Meco FD, Lieberman F, Zhu J, Stragliotto G, Tran DD, ... Brem S, et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma Jama. 318: 2306-2316. DOI: 10.5167/Uzh-143757 |
0.372 |
|
| 2017 |
Chawla S, Wang S, Verma G, Skolnik A, Karpf L, Desiderio L, Brem S, Peters K, Poptani H, Mohan S. Abstract CT068: Tumor treating fields in patients with glioblastomas: Evaluation of treatment response using advanced mr imaging techniques Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Ct068 |
0.374 |
|
| 2017 |
Bagley SJ, O’Rourke DM, Brem S, Linette GP, Desai AS. PATH-02. USE OF RNAseq TO IDENTIFY TUMOR CELL AND MICROENVIRONMENT FACTORS ASSOCIATED WITH IMMUNE CYTOLYTIC ACTIVITY IN GLIOBLASTOMA Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox168.693 |
0.315 |
|
| 2016 |
Mohan S, Chawla S, Wang S, Verma G, Skolnik A, Brem S, Peters KB, Poptani H. Assessment of early response to tumor-treating fields in newly diagnosed glioblastoma using physiologic and metabolic MRI: initial experience. Cns Oncology. PMID 27076281 DOI: 10.2217/Cns-2016-0003 |
0.371 |
|
| 2016 |
Evans SM, Putt M, Yang XY, Lustig RA, Martinez-Lage M, Williams D, Desai A, Wolf R, Brem S, Koch CJ. Initial evidence that blood-borne microvesicles are biomarkers for recurrence and survival in newly diagnosed glioblastoma patients. Journal of Neuro-Oncology. PMID 26746692 DOI: 10.1007/S11060-015-2051-3 |
0.363 |
|
| 2016 |
O'Rourke DM, Nasrallah M, Morrissette JJ, Melenhorst JJ, Lacey SF, Mansfield K, Martinez-Lage M, Desai AS, Brem S, Maloney E, Mohan S, Wang S, Verma G, Navenot J, Shen A, et al. Pilot study of T cells redirected to EGFRvIII with a chimeric antigen receptor in patients with EGFRvIII+ glioblastoma. Journal of Clinical Oncology. 34: 2067-2067. DOI: 10.1200/Jco.2016.34.15_Suppl.2067 |
0.354 |
|
| 2016 |
O’Rourke DM, Nasrallah MP, Morrissette J, Melenhorst JJ, Lacey SF, Mansfield K, Martinez-Lage M, Desai A, Brem S, Maloney E, Mohan S, Wang S, Verma G, Navenot J, Shen A, et al. Abstract LB-083: Phase I study of T cells redirected to EGFRvIII with a chimeric antigen receptor in patients with EGFRvIII+ glioblastoma Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-083 |
0.363 |
|
| 2015 |
Chowdhury IH, Ojerholm E, McMillan MT, Miller D, Kolker JD, Kurtz G, Dorsey JF, Nagda SN, Geiger GA, Brem S, O'Rourke DM, Zager EL, Gangadhar T, Schuchter L, Lee JY, et al. Novel risk scores for survival and intracranial failure in patients treated with radiosurgery alone to melanoma brain metastases. Radiation Oncology (London, England). 10: 248. PMID 26626714 DOI: 10.1186/S13014-015-0553-Y |
0.313 |
|
| 2015 |
Vogel J, Ojerholm E, Hollander A, Briola C, Mooij R, Bieda M, Kolker J, Nagda S, Geiger G, Dorsey J, Lustig R, O'Rourke DM, Brem S, Lee J, Alonso-Basanta M. Intracranial control after Cyberknife radiosurgery to the resection bed for large brain metastases. Radiation Oncology (London, England). 10: 221. PMID 26520568 DOI: 10.1186/S13014-015-0523-4 |
0.361 |
|
| 2015 |
Wang S, Martinez-Lage M, Sakai Y, Chawla S, Kim SG, Alonso-Basanta M, Lustig RA, Brem S, Mohan S, Wolf RL, Desai A, Poptani H. Differentiating Tumor Progression from Pseudoprogression in Patients with Glioblastomas Using Diffusion Tensor Imaging and Dynamic Susceptibility Contrast MRI. Ajnr. American Journal of Neuroradiology. PMID 26450533 DOI: 10.3174/Ajnr.A4474 |
0.341 |
|
| 2015 |
Abdullah KG, Ramayya A, Thawani JP, Macyszyn L, Martinez-Lage M, O'Rourke DM, Brem S. Factors associated with increased survival after surgical resection of glioblastoma in octogenarians. Plos One. 10: e0127202. PMID 25978638 DOI: 10.1371/Journal.Pone.0127202 |
0.342 |
|
| 2015 |
Singh N, Parker D, Macyszyn L, O'Rourke DM, Brem S, Verma R. NIMG-62USING A MULTI-COMPARTMENT DIFFUSION MODEL TO CHARACTERIZE EDEMA DIFFERENCES BETWEEN GBMS AND BRAIN METASTASES Neuro-Oncology. 17: v168.2-v168. DOI: 10.1093/Neuonc/Nov225.62 |
0.336 |
|
| 2015 |
O'Rourke D, Desai A, Morrissette J, Martinez-Lage M, Nasrallah M, Brem S, Maloney E, Shen A, Mohan S, Wang S, Verma G, Lacey S, Melenhorst J, Navenot J, Zheng Z, et al. IMCT-15PILOT STUDY OF T CELLS REDIRECTED TO EGFRvIII WITH A CHIMERIC ANTIGEN RECEPTOR IN PATIENTS WITH EGFRvIII+ GLIOBLASTOMA Neuro-Oncology. 17: v110.4-v111. DOI: 10.1093/Neuonc/Nov218.15 |
0.373 |
|
| 2015 |
Cooke M, Saxena D, Kao G, Aguarin L, Cheng P, Steinmetz D, Fenolallal G, Alonso-Basanta M, O'Rourke D, Brem S, Lustig R, Dorsey J. CBM-03MOLECULAR CHARACTERIZATION OF GLIOMA CIRCULATING TUMOR CELLS (gCTCs) AT SINGLE CELL RESOLUTION Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov211.03 |
0.431 |
|
| 2015 |
Chowdhury I, Ojerholm EJ, McMillan MT, Miller D, Kolker JD, Kurtz G, Dorsey JF, Nagda S, Geiger GA, Brem S, O'Rourke DM, Zager E, Lee JY, Alonso-Basanta M. Novel Prognostic Scores for Survival and Intracranial Failure in Patients Treated With Radiosurgery Alone to Melanoma Brain Metastases International Journal of Radiation Oncology Biology Physics. 93. DOI: 10.1016/J.Ijrobp.2015.07.818 |
0.346 |
|
| 2014 |
Rosenfeld MR, Ye X, Supko JG, Desideri S, Grossman SA, Brem S, Mikkelson T, Wang D, Chang YC, Hu J, McAfee Q, Fisher J, Troxel AB, Piao S, Heitjan DF, et al. A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy. 10: 1359-68. PMID 24991840 DOI: 10.4161/Auto.28984 |
0.33 |
|
| 2014 |
Nasrallah MP, Martinez-Lage M, Fox A, Sukhadia S, Desai A, O'Rourke DM, Brem S, Roth D, Morrissette JJD, Daber RD. Abstract 3428: Validation and utilization of next generation sequencing in the clinical assessment of gliomas Cancer Research. 74: 3428-3428. DOI: 10.1158/1538-7445.Am2014-3428 |
0.322 |
|
| 2013 |
Brem S, Meyers CA, Palmer G, Booth-Jones M, Jain S, Ewend MG. Preservation of neurocognitive function and local control of 1 to 3 brain metastases treated with surgery and carmustine wafers. Cancer. 119: 3830-8. PMID 24037801 DOI: 10.1002/Cncr.28307 |
0.333 |
|
| 2013 |
Chacko AM, Li C, Pryma DA, Brem S, Coukos G, Muzykantov V. Targeted delivery of antibody-based therapeutic and imaging agents to CNS tumors: crossing the blood-brain barrier divide. Expert Opinion On Drug Delivery. 10: 907-26. PMID 23751126 DOI: 10.1517/17425247.2013.808184 |
0.367 |
|
| 2013 |
Abdullah KG, Lubelski D, Nucifora PG, Brem S. Use of diffusion tensor imaging in glioma resection. Neurosurgical Focus. 34: E1. PMID 23544405 DOI: 10.3171/2013.1.Focus12412 |
0.32 |
|
| 2012 |
Seaman B, Brem S, Fromm A, Staller A, McCardle T, Jain S. Intracranial spread of Merkel cell carcinoma to the cerebellopontine angle. Journal of Cutaneous Medicine and Surgery. 16: 54-60. PMID 22417997 DOI: 10.1177/120347541201600111 |
0.381 |
|
| 2012 |
Chinnaiyan P, Chowdhary S, Potthast L, Prabhu A, Tsai YY, Sarcar B, Kahali S, Brem S, Yu HM, Rojiani A, Murtagh R, Pan E. Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma. Neuro-Oncology. 14: 93-100. PMID 22028388 DOI: 10.1093/Neuonc/Nor187 |
0.323 |
|
| 2011 |
Ewend MG, Meyers CA, Silva E, Booth-Jones M, Jain S, Brem S. Effects of surgery with BCNU wafer placement on neurocognitive function in patients with one to three brain metastases. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2015. PMID 28023865 DOI: 10.1200/Jco.2011.29.15_Suppl.2015 |
0.364 |
|
| 2011 |
Wong ET, Gautam S, Malchow C, Lun M, Pan E, Brem S. Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis. Journal of the National Comprehensive Cancer Network : Jnccn. 9: 403-7. PMID 21464145 DOI: 10.6004/Jnccn.2011.0037 |
0.315 |
|
| 2011 |
Egan KM, Thompson RC, Nabors LB, Olson JJ, Brat DJ, Larocca RV, Brem S, Moots PL, Madden MH, Browning JE, Ann Chen Y. Cancer susceptibility variants and the risk of adult glioma in a US case-control study. Journal of Neuro-Oncology. 104: 535-42. PMID 21203894 DOI: 10.1007/S11060-010-0506-0 |
0.33 |
|
| 2011 |
Wong ET, Brem S. Taming glioblastoma by targeting angiogenesis: 3 years later. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 124-6. PMID 21135277 DOI: 10.1200/Jco.2010.32.5282 |
0.353 |
|
| 2011 |
Brem S, Sampath R, Yu D, Staller A, Obadia M, Ewend MG. Stereotactic volumetric resection, intracavitary carmustine wafers, and radiation therapy for brain metastases: The Moffitt Cancer Center experience. Journal of Clinical Oncology. 29: 2077-2077. DOI: 10.1200/Jco.2011.29.15_Suppl.2077 |
0.334 |
|
| 2011 |
Egan KM, Nabors LB, Olson JJ, Browning JE, Madden MH, Chen YA, Brem S, Brat DJ, Sontheimer H, Tran ND, Thompson RC. Abstract 876: Genetic variation in the voltage-gated chloride channel family members CLCN2 and CLCN3 in relation to glioma risk and outcome Cancer Research. 71: 876-876. DOI: 10.1158/1538-7445.Am2011-876 |
0.307 |
|
| 2010 |
Chinnaiyan P, Chowdhary S, Brem S, Yu M, Murtagh R, Rojiani A, Tsai Y, Pan E. A phase I trial of vorinostat in combination with bevacizumab and irinotecan in recurrent glioblastoma. Journal of Clinical Oncology. 28. DOI: 10.1200/Jco.2010.28.15_Suppl.Tps150 |
0.308 |
|
| 2010 |
Rosenfeld MR, Grossman SA, Brem S, Mikkelsen T, Wang D, Piao S, Davis LE, O'Dwyer PJ, Amaravadi RK. Pharmacokinetic analysis and pharmacodynamic evidence of autophagy inhibition in patients with newly diagnosed glioblastoma treated on a phase I trial of hydroxychloroquine in combination with adjuvant temozolomide and radiation (ABTC 0603). Journal of Clinical Oncology. 28: 3086-3086. DOI: 10.1200/Jco.2010.28.15_Suppl.3086 |
0.312 |
|
| 2010 |
Brem S, Meyers CA, Booth-Jones M, Jain S, Ewend MG. A prospective study of surgery plus biodegradable carmustine wafers for local control and neurocognitive function in 39 patients with one to three brain metastases: Preliminary results. Journal of Clinical Oncology. 28: 2066-2066. DOI: 10.1200/Jco.2010.28.15_Suppl.2066 |
0.387 |
|
| 2010 |
Murphy SF, Banasiak M, Yee G, Wotoczek-Obadia M, Malafa M, Rojiani MV, Rojiani AM, Tofilon P, Henderson F, Djakiew D, Forsyth PA, Senger DL, Brem S. Abstract 5271: Ibuprofen, an inhibitor of angiogenesis, enhances radiosensitivity and suppresses glioma invasion: Role of p75NTRand VEGF Cancer Research. 70: 5271-5271. DOI: 10.1158/1538-7445.Am10-5271 |
0.329 |
|
| 2010 |
Rojiani MV, Brem S, Murphy S, Obadia M, Rojiani AM. Abstract 3444: The role of p75ntrand TIMP-1 in U251 malignant glioma cells Cancer Research. 70: 3444-3444. DOI: 10.1158/1538-7445.Am10-3444 |
0.363 |
|
| 2009 |
Potthast L, Chowdhary S, Pan E, Yu D, Zhu W, Brem S. The infiltrative, diffuse pattern of recurrence in patients with malignant gliomas treated with bevacizumab. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 2057. PMID 27964663 DOI: 10.1200/Jco.2009.27.15_Suppl.2057 |
0.322 |
|
| 2009 |
Nabors LB, Mikkelsen T, Batchelor T, Lesser G, Rosenfeld M, Ye X, Piantadosi S, Olson J, Brem S, Grossman S. NABTT 0306: A randomized phase II trial of EMD 121974 in conjunction with concomitant and adjuvant temozolomide with radiation therapy in patients with newly diagnosed glioblastoma multiforme (GBM). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 2001. PMID 27964566 DOI: 10.1200/Jco.2009.27.15_Suppl.2001 |
0.329 |
|
| 2008 |
Wong ET, Brem S. Antiangiogenesis treatment for glioblastoma multiforme: challenges and opportunities. Journal of the National Comprehensive Cancer Network : Jnccn. 6: 515-22. PMID 18492463 DOI: 10.6004/Jnccn.2008.0039 |
0.335 |
|
| 2008 |
Ewend MG, Morris DE, Carey LA, Ladha AM, Brem S. Guidelines for the initial management of metastatic brain tumors: role of surgery, radiosurgery, and radiation therapy. Journal of the National Comprehensive Cancer Network : Jnccn. 6: 505-13; quiz 514. PMID 18492462 DOI: 10.6004/Jnccn.2008.0038 |
0.398 |
|
| 2007 |
Wong ET, Brem S. Taming glioblastoma: targeting angiogenesis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 4705-6. PMID 17947716 DOI: 10.1200/Jco.2007.13.1037 |
0.406 |
|
| 2007 |
Barami K, Grow A, Brem S, Dagnew E, Sloan AE. Vascular complications after radiosurgery for meningiomas. Neurosurgical Focus. 22: E9. PMID 17608362 DOI: 10.3171/Foc.2007.22.3.10 |
0.326 |
|
| 2007 |
Ewend MG, Brem S, Gilbert M, Goodkin R, Penar PL, Varia M, Cush S, Carey LA. Treatment of single brain metastasis with resection, intracavity carmustine polymer wafers, and radiation therapy is safe and provides excellent local control. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 3637-41. PMID 17575228 DOI: 10.1158/1078-0432.Ccr-06-2095 |
0.381 |
|
| 2006 |
Khan MA, Andrews S, Ismail-Khan R, Munster PN, Brem S, King J, Reintgen DS, Sondak VK, Daud AI. Overall and progression-free survival in metastatic melanoma: analysis of a single-institution database. Cancer Control : Journal of the Moffitt Cancer Center. 13: 211-7. PMID 16885917 DOI: 10.1177/107327480601300308 |
0.347 |
|
| 2005 |
Brem S, Panattil JG. An era of rapid advancement: diagnosis and treatment of metastatic brain cancer. Neurosurgery. 57: S5-9; discusssion S1. PMID 16237289 DOI: 10.1093/Neurosurgery/57.Suppl_5.S4-5 |
0.39 |
|
| 2005 |
Young RJ, Sills AK, Brem S, Knopp EA. Neuroimaging of metastatic brain disease. Neurosurgery. 57: S10-23; discusssion . PMID 16237282 DOI: 10.1227/01.Neu.0000182774.54193.37 |
0.342 |
|
| 2005 |
Gallia GL, Brem S, Brem H. Local treatment of malignant brain tumors using implantable chemotherapeutic polymers. Journal of the National Comprehensive Cancer Network : Jnccn. 3: 721-8. PMID 16194460 DOI: 10.6004/Jnccn.2005.0042 |
0.366 |
|
| 2005 |
Brem S, Grossman SA, Carson KA, New P, Phuphanich S, Alavi JB, Mikkelsen T, Fisher JD. Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma. Neuro-Oncology. 7: 246-53. PMID 16053699 DOI: 10.1215/S1152851704000869 |
0.325 |
|
| 2004 |
Chiocca EA, Abbed KM, Tatter S, Louis DN, Hochberg FH, Barker F, Kracher J, Grossman SA, Fisher JD, Carson K, Rosenblum M, Mikkelsen T, Olson J, Markert J, Rosenfeld S, ... ... Brem S, et al. A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Molecular Therapy : the Journal of the American Society of Gene Therapy. 10: 958-66. PMID 15509513 DOI: 10.1016/J.Ymthe.2004.07.021 |
0.325 |
|
| 2004 |
Paris D, Townsend K, Quadros A, Humphrey J, Sun J, Brem S, Wotoczek-Obadia M, DelleDonne A, Patel N, Obregon DF, Crescentini R, Abdullah L, Coppola D, Rojiani AM, Crawford F, et al. Inhibition of angiogenesis by Abeta peptides. Angiogenesis. 7: 75-85. PMID 15302999 DOI: 10.1023/B:Agen.0000037335.17717.Bf |
0.304 |
|
| 2004 |
Brem S, Horton J. Basis for progress in brain tumor therapy Cancer Control. 11: 142. DOI: 10.1177/107327480401100301 |
0.384 |
|
| 2003 |
Tatter SB, Shaw EG, Rosenblum ML, Karvelis KC, Kleinberg L, Weingart J, Olson JJ, Crocker IR, Brem S, Pearlman JL, Fisher JD, Carson K, Grossman SA. An inflatable balloon catheter and liquid 125I radiation source (GliaSite Radiation Therapy System) for treatment of recurrent malignant glioma: multicenter safety and feasibility trial. Journal of Neurosurgery. 99: 297-303. PMID 12924704 DOI: 10.3171/Jns.2003.99.2.0297 |
0.377 |
|
| 2003 |
Brem S. Brain tumor therapy: What lies clearly at hand Cancer Control. 10: 107-108. DOI: 10.1177/107327480301000201 |
0.37 |
|
| 2002 |
Baker MJ, Brem S, Daniels S, Sherman B, Phuphanich S. Complete response of a recurrent, multicentric malignant glioma in a patient treated with phenylbutyrate. Journal of Neuro-Oncology. 59: 239-42. PMID 12241121 DOI: 10.1023/A:1019905127442 |
0.383 |
|
| 1999 |
Brem S. Angiogenesis and Cancer Control: From Concept to Therapeutic Trial. Cancer Control : Journal of the Moffitt Cancer Center. 6: 436-458. PMID 10758576 DOI: 10.1177/107327489900600502 |
0.328 |
|
| 1998 |
Brem S. Brain Tumor Therapy: New Lights on the Horizon. Cancer Control : Journal of the Moffitt Cancer Center. 5: 95-97. PMID 10761020 DOI: 10.1177/107327489800500208 |
0.351 |
|
| 1998 |
Clarke LP, Velthuizen RP, Clark M, Gaviria J, Hall L, Goldgof D, Murtagh R, Phuphanich S, Brem S. MRI measurement of brain tumor response: comparison of visual metric and automatic segmentation. Magnetic Resonance Imaging. 16: 271-9. PMID 9621968 DOI: 10.1016/S0730-725X(97)00302-0 |
0.358 |
|
| 1998 |
Davis FG, Freels S, Grutsch J, Barlas S, Brem S. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. Journal of Neurosurgery. 88: 1-10. PMID 9420066 DOI: 10.3171/Jns.1998.88.1.0001 |
0.398 |
|
| 1998 |
Brem S. Ten Best Readings on Brain Tumors Cancer Control. 5: 1-2. DOI: 10.1177/107327489800500210 |
0.367 |
|
| 1997 |
Fernandez PM, Brem S. Malignant brain tumors in the elderly. Clinics in Geriatric Medicine. 13: 327-38. PMID 9115454 DOI: 10.1016/S0749-0690(18)30172-1 |
0.409 |
|
| 1995 |
Brem S, Rozental JM, Moskal JR. What is the etiology of human brain tumors? A report on the first Lebow conference. Cancer. 76: 709-13. PMID 8625170 DOI: 10.1002/1097-0142(19950815)76:4<709::Aid-Cncr2820760427>3.0.Co;2-C |
0.368 |
|
| 1995 |
Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, Black K, Sisti M, Brem S, Mohr G. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet. 345: 1008-12. PMID 7723496 DOI: 10.1016/S0140-6736(95)90755-6 |
0.32 |
|
| 1995 |
Gately S, Tsanaclis AMC, Takano S, Klagsbrun M, Brem S. Cells transfected with the basic fibroblast growth factor gene fused to a signal sequence are invasive in vitro and in situ in the brain Neurosurgery. 36: 780-788. PMID 7596510 DOI: 10.1227/00006123-199504000-00020 |
0.325 |
|
| 1994 |
Takano S, Gately S, Engelhard H, Tsanaclis AMC, Brem S. Suramin inhibits glioma cell proliferation in vitro and in the brain Journal of Neuro-Oncology. 21: 189-201. PMID 7699415 DOI: 10.1007/Bf01063768 |
0.351 |
|
| 1991 |
Tsanaclis AM, Robert F, Michaud J, Brem S. The Cycling Pool of Cells within Human Brain Tumors: In Situ Cytokinetics Using the Monoclonal Antibody Ki-67 Canadian Journal of Neurological Sciences / Journal Canadien Des Sciences Neurologiques. 18: 12-17. PMID 1645210 DOI: 10.1017/S0317167100031243 |
0.359 |
|
| 1990 |
Brem S, Tsanaclis AM, Zagzag D. Anticopper treatment inhibits pseudopodial protrusion and the invasive spread of 9L gliosarcoma cells in the rat brain. Neurosurgery. 26: 391-6. PMID 2320207 DOI: 10.1097/00006123-199003000-00003 |
0.363 |
|
| 1989 |
Brien SE, Zagzag D, Brem S. Rapid in situ cellular kinetics of intracerebral tumor angiogenesis using a monoclonal antibody to bromodeoxyuridine. Neurosurgery. 25: 715-9. PMID 2479879 DOI: 10.1097/00006123-198911000-00005 |
0.385 |
|
| 1989 |
Zagzag D, Goldenberg M, Brem S. Angiogenesis and blood-brain barrier breakdown modulate CT contrast enhancement: an experimental study in a rabbit brain-tumor model. Ajr. American Journal of Roentgenology. 153: 141-6. PMID 2472056 DOI: 10.2214/Ajr.153.1.141 |
0.388 |
|
| 1986 |
Arbit E, And JW, Brem S. Optic nerve meningioma: A case for expectant therapy Neuro-Ophthalmology. 6: 129-135. DOI: 10.3109/01658108608997340 |
0.334 |
|
| 1978 |
Patz A, Brem S, Finkelstein D, Chen C, Lutty G, Bennett A, Coughlin WR, Gardner J. A New Approach to the Problem of Retinal Neovascularization Ophthalmology. 85: 626-637. PMID 580956 DOI: 10.1016/S0161-6420(78)35640-2 |
0.32 |
|
| 1976 |
Brem S. The role of vascular proliferation in the growth of brain tumors Clinical Neurosurgery. 23: 440-453. PMID 975695 DOI: 10.1093/Neurosurgery/23.Cn_Suppl_1.440 |
0.396 |
|
| 1972 |
Brem S, Cotran R, Folkman J. Tumor Angiogenesis: A Quantitative Method for Histologic Grading Journal of the National Cancer Institute. 48: 347-356. DOI: 10.1093/Jnci/48.2.347 |
0.346 |
|
| Show low-probability matches. |